DUBLIN – Pfizer Inc.'s and Eli Lilly and Co.'s venerable antibody, tanezumab, a longtime clinical candidate for various pain indications, is lumbering toward the finish line. The two partners reported a second positive phase III readout inside a month. This time around, it's in patients with chronic lower back pain. The higher dose of the drug (10 mg) used in the study attained the primary endpoint of a statistically significant improvement in pain at 16 weeks, as compared with placebo. A lower dose (5 mg) did not attain statistical significance at the same time point.